Contentious Alzheimer ' s Drug Likely to Get National Pay Plan Contentious Alzheimer ' s Drug Likely to Get National Pay Plan

CMS said it is working toward a national Medicare coverage policy for the controversial Alzheimer ' s drug aducanumab. Insurers have suggested CMS limit coverage of the drug pending proof of its benefit.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Psychiatry News Source Type: news